M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Epiphany Biosciences announces positive results from phase IIb trial in shingles
19 November - US-based company developing therapeutic products and diagnostic technologies Epiphany Biosciences announced today results from its Phase IIb dose-ranging study of EPB-348 (valomaciclovir) in patients with shingles (herpes zoster) infection.EPB-348 is a potent inhibitor of herpes...
If you want to view the full text, you must first purchase archive credits.
Return to Archives
New Search